Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

After the publication of this work [1] the authors have reported that in Table 3 The letter "T" in columns 5 and 7 should not be there.

RCT Entities:   Population Interventions Outcomes

Correction to: Breast Cancer Res

https://doi.org/10.1186/s13058-019-1196-y

After the publication [1] the authors report corrections for Table 3, for the headers of columns 5 and 7, which should read as follows: Column 5 Header: P-value for pCR, T vs Other Arms in HR+, and Column 7 Header: P-value for pCR, T vs Other Arms in HR–.

The correct version of the table can be found below:

Table 3

NSABP FB-7: Pathologic complete response (pCR) (breast and nodes) by treatment arm and HR status

Treatment arms,n = 42 each arm	Total pCR	P-value for pCR T vs Other Arms in all patientsa	pCR HR+	P-value for pCR T vs Other Arms in HR+ b	pCR HR−	P-value for pCR T vs Other Arms in HR− b	P-value HR+ vs HR−
Arm 1 (T)	16/41 (39.0%)	NA	8/27 (29.6%)	NA	8/14 (57.1%)	NA	0.11
Arm 2 (N)	14/42 (33.3%)	0.63	8/29 (27.6%)	1	6/13 (46.2%)	0.71	0.30
Arm 3 (T plus N)	21/42 (50%)	0.22	7/23 (30.4%)	1	14/19 (73.7%)	0.46	0.01
All arms	51/126 (40%)		23/79 (29%)		28/46 (61%)		0.001

Abbreviations: T, trastuzumab; N, neratinib

aCMH test stratified for the time period the patients were randomized to the study (prior/after the addition of Arm 3)

bFisher’s exact test